Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Joseph Victor; Leroy Hood; and More

Premium

DVS Sciences has appointed Joseph Victor president and CEO. He will assume the role from DVS co-founder Scott Tanner, who will become the company’s chief technology officer and general manager of its Canadian operations.

Previously, Victor was president and CEO of Applied Precision, which was recently acquired by GE Healthcare.


PrimeraDx this week announced that it has appointed Leroy Hood to its scientific advisory board.

Hood has helped found several research and commercial enterprises, including Applied Biosystems (now part of Life Technologies), Amgen, and the Institute for Systems Biology, where he currently holds the position of president. He has won several awards including the 2003 Association for Molecular Pathology award for excellence in molecular diagnostics; the Academy of Engineering's Russ Prize; the Lasker Award; and the Kyoto Prize. He has more than 700 peer-reviewed articles and is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.


Cellzome scientific founder Gitte Neubauer this week won the EU Women Innovators Award, a €100,000 ($133,000) prize given by the European Commission Innovation Union, in recognition of her role in launching the company.

Neubauer heads Cellzome’s chemoproteomics screening facility and is a member of the advisory editorial board of the magazine Drug Discovery Today and the industrial advisory board of the biotechnology faculty of the University of Applied Sciences in Mannheim, Germany.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.